MARKET

ETNB

ETNB

89Bio, Inc.
NASDAQ
8.38
+0.13
+1.58%
Opening 13:00 04/26 EDT
OPEN
8.30
PREV CLOSE
8.25
HIGH
8.45
LOW
8.19
VOLUME
160.40K
TURNOVER
0
52 WEEK HIGH
22.93
52 WEEK LOW
6.58
MARKET CAP
797.98M
P/E (TTM)
-4.1946
1D
5D
1M
3M
1Y
5Y
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Madrigal Pharmaceuticals, Inc. Recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035. The company will have to overcome two challenges to maintain its "first mover" advantage in the market. Madrigal has to manage the launch of Rezdiffra and keep an eye on future competitors.
Seeking Alpha · 1d ago
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 2d ago
89bio Coverage Assumed by B of A Securities at Buy
Dow Jones · 4d ago
89bio Price Target Announced at $30.00/Share by B of A Securities
Dow Jones · 4d ago
B of A Securities Assumes 89bio at Buy, Announces Price Target of $30
Benzinga · 4d ago
Weekly Report: what happened at ETNB last week (0415-0419)?
Weekly Report · 4d ago
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 6d ago
89bio Enhances Board with Biopharma Veteran Martin Babler
TipRanks · 04/17 20:22
More
About ETNB
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.

Webull offers 89bio Inc stock information, including NASDAQ: ETNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ETNB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ETNB stock methods without spending real money on the virtual paper trading platform.